Combined immunoscore of CD103 and CD3 identifies long-term survivors in high-grade serous ovarian cancer

International Journal of Gynecological Cancer

Volumn 26, Issue 4, 2016, Pages 671-679

  Bösmüller, Hans Christian ^a   Wagner, Philipp ^a   Peper, Janet Kerstin ^b   Schuster, Heiko ^b   Pham, Deborah Lam ^a   Greif, Karen ^a   Beschorner, Christine ^a   Rammensee, Hans Georg ^b,c   Stevanović, Stefan ^b,c   Fend, Falko ^a,c   Staebler, Annette ^a,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

HGSC High grade serous ovarian cancer; OS Overall survival; TIL Tumor infiltrating lymphocyte; TMA tissue microarray

Indexed keywords

CD103 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; PLATINUM; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TRANSCRIPTION FACTOR FOXP3; UVOMORULIN; ALPHA E INTEGRINS; ALPHA INTEGRIN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVOR; CELL DENSITY; CHEMOSENSITIVITY; CYTOREDUCTIVE SURGERY; FEMALE; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MEDIAN SURVIVAL TIME; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; T LYMPHOCYTE; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; CANCER GRADING; CD8+ T LYMPHOCYTE; CYSTADENOCARCINOMA; ENZYME IMMUNOASSAY; FOLLOW UP; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVOR; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD3; BIOMARKERS, TUMOR; CD8-POSITIVE T-LYMPHOCYTES; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHA CHAINS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; SURVIVORS; TIME FACTORS;

EID: 84965102043     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000672     Document Type: Article

References (33)

1. Hwang WT, Adams SF, Tahirovic E, Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-Analysis. Gynecol Oncol. 2012; 124: 192-198.
2. Al-Attar A, Shehata M, Durrant L, T cell density and location can influence the prognosis of ovarian cancer. Pathol Oncol Res. 2010; 16: 361-370.
3. Tomsova M, Melichar B, Sedlakova I, Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol. 2008; 108: 415-420.
4. Milne K, Alexander C, Webb JR, Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med. 2012; 10: 33.
5. Webb JR, Milne K, Watson P, Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2014; 20: 434-444.
6. Webb JR, Wick DA, Nielsen JS, Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 integrin) in high-grade serous ovarian cancer. Gynecol Oncol. 2010; 118: 228-236.
7. Webb JR, Milne K, Nelson BH,. Location, location, location: CD103 demarcates intraepithelial, prognostically favorable CD8 tumor-infiltrating lymphocytes in ovarian cancer. Oncoimmunology. 2014; 3: e27668.
8. Sarrabayrouse G, Corvaisier M, Ouisse LH, Tumor-reactive CD4+ CD8β + CD103+ βT cells: a prevalent tumor-reactive T-cell subset in metastatic colorectal cancers. Int J Cancer. 2011; 128: 2923-2932.
9. Adams SF, Levine DA, Cadungog MG, Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer. 2009; 115: 2891-2902.
10. Clarke B, Tinker AV, Lee CH, Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009; 22: 393-402.
11. Bachmayr-Heyda A, Aust S, Heinze G, Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients-A study of the OVCAD consortium. BMC Cancer. 2013; 13: 422.
12. Malpica A,. Grading of ovarian cancer: a histotype-specific approach. Int J Gynecol Pathol. 2008; 27: 175-181.
13. Malpica A, Deavers MT, Lu K, Grading ovarian serous carcinoma using a two-Tier system. Am J Pathol. 2004; 28: 496-504.
14. Zhang L, Conejo-Garcia JR, Katsaros D, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348: 203-213.
15. Krempski J, Karyampudi L, Behrens MD, Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol. 2011; 186: 6905-6913.
16. Barnett JC, Bean SM, Whitaker RS, Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol. 2010; 116: 556-562.
17. Martinet L, Poupot R, Mirshahi P, Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. Int J Cancer. 2010; 126: 2143-2152.
18. Robins HS, Ericson NG, Guenthoer J, Digital genomic quantification of tumor-infiltrating lymphocytes. Sci Transl Med. 2013; 5: 214ra169.
19. Thompson MS, Mok SC,. Immunopathogenesis of ovarian cancer. Minerva Med. 2009; 100: 357-370.
20. Yang T, Wall EM, Milne K, CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism. Clin Cancer Res. 2007; 13: 7172-7180.
21. Milne K, Kobel M, Kalloger SE, Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009; 4: e6412.
22. Preston CC, Maurer MJ, Oberg AL, The ratios of CD8+ T cells to CD4 + CD25+ FOXP3+ and FOXP3-T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One. 2013; 8: e80063.
23. Sato E, Olson SH, Ahn J, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc National Acad Sci U S A. 2005; 102: 18538-18543.
24. Stumpf M, Hasenburg A, Riener MO, Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer. 2009; 101: 1513-1521.
25. Webb JR, Milne K, Nelson BH,. PD-1 and CD103 are widely coexpressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer. Cancer Immunol Res. 2015; 3: 926-935.
26. Gooden MJ, de Bock GH, Leffers N, The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-Analysis. Br J Cancer. 2011; 105: 93-103.
27. Ling KL, Dulphy N, Bahl P, Modulation of CD103 expression on human colon carcinoma-specific CTL. J Immunol. 2007; 178: 2908-2915.
28. Mackay LK, Rahimpour A, Ma JZ, The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat Immunol. 2013; 14: 1294-1301.
29. Weng D, Song B, Durfee J, Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int J Cancer. 2011; 129: 1990-2001.
30. Emerson RO, Sherwood AM, Rieder MJ, High-Throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J Pathol. 2013; 231: 433-440.
31. Franciszkiewicz K, Le Floch A, Jalil A, Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res. 2009; 69: 6249-6255.
32. Lai D, Wang F, Chen Y, Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes. Cancer Immunol Immunother. 2012; 61: 979-989.
33. Bamias A, Tsiatas ML, Kafantari E, Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3 + CD56+ cells with platinum resistance. Gynecol Oncol. 2007; 106: 75-81.